Brief Observation|Articles in Press

Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 Year

Published:February 22, 2023DOI:



      Excess mortality remains the cornerstone concern despite dual antiplatelet therapy (DAPT) after acute coronary syndrome. Some data suggest that shorter periods than 12 months of DAPT diminish bleeding risks yet still provide adequate vascular protection and improving survival. However, the precise timing of deaths after acute coronary syndrome has not been mapped in many studies. This knowledge may be critical for defining optimal treatment duration.


      Access was gained to the data set for the Platelet Inhibition and Outcomes (PLATO) trial, which was issued by the Food and Drug Administration, in which post hoc analyses of timing of death events during DAPT (with either aspirin/ticagrelor or aspirin/clopidogrel) were performed. All-cause individual deaths were counted and plotted over time from day 1 to day 365 after the index event.


      Among 18,624 enrollees, 938 total deaths were reported to the Food and Drug Administration in PLATO. After exclusion of deceased patients with missing dates, randomization errors, and deaths beyond 1 year of follow-up, 913 fatalities (509 after clopidogrel and 404 after ticagrelor) were analyzed. The PLATO records did not indicate where exactly deaths occurred making impossible to triage in the hospital versus outpatient fatalities. Most frequent deaths occurred within the Day 1 (n = 41); Day 2 (n = 48); and Day 3 (n = 33) and overall during the first week (n = 202; 22.1%) after the index acute coronary syndrome, with a gradual decline after Day 10 and Day 60, reaching background counts after Day 220.


      Focusing on mortality reduction, this large data set may support a shorter than 12 months’ duration of DAPT.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Giustino G
        • Baber U
        • Sartori S
        • et al.
        Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials.
        J Am Coll Cardiol. 2015; 65: 1298-1310
        • Watanabe H
        • Domei T
        • Morimoto T
        • et al.
        Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial.
        JAMA. 2019; 321: 2414-2427
        • Valgimigli M
        • Frigoli E
        • Dik Heg D
        • et al.
        Dual antiplatelet therapy after PCI in patients at high bleeding risk.
        N Engl J Med. 2021; 385: 1643-1655
        • Mauri L
        • Kereiakes DJ
        • Yeh RW
        • et al.
        Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
        N Engl J Med. 2014; 371: 2155-2166
        • Gelbenegger G
        • Erari-Canyurt U
        • Grafender J
        • et al.
        Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: a meta-analysis.
        Vasc Pharm. 2021; 138106858
        • Kamran H
        • Jneid H
        • Kayani WT
        • et al.
        Oral antiplatelet therapy after acute coronary syndrome: a review.
        JAMA. 2021; 325: 1545-1555
        • Majithia A
        • Deepak L
        • Bhatt D
        Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention.
        Interv Cardiol Clin. 2017; 6: 25-37
        • Wallentin L
        • Becker RC
        • Budaj A
        • et al.
        Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
        N Engl J Med. 2009; 61: 1045-1057
      1. US Food and Drug Administration (FDA). The FDA ticagrelor review of complete response. Available at: Accessed August 20, 2022.

        • Wang H
        • Qi J
        • Li Y.
        • et al.
        Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.
        Br J Clin Pharmacol. 2018; 84: 88-96
        • Schilling U
        • Dingemanse J
        • Ufer M
        Pharmacokinetics and pharmacodynamics of approved and investigational P2Y12 receptor antagonists.
        Clin Pharmacokinet. 2020; : 59545-59566
        • Serebruany V
        • Tanguay J-F
        • Benavides MA
        • et al.
        Verifying death reports in the platelet inhibition and patient outcomes (PLATO) trial.
        Amer J Therap. 2020; 27: e563-e572
        • Yin S-H
        • Hu P
        • Wang B
        • et al.
        Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis.
        BMJ. 2019; 365: l2222
        • Serebruany VL
        • Atar D.
        Central adjudication of myocardial infarction in outcome-driven clinical trials - Common patterns in TRITON, RECORD, and PLATO?.
        Thromb Haemost. 2012; 108: 412-414
        • Verheugt FW.
        Outcomes of positive randomised controlled clinical trials: double-blind or double vision?.
        Thromb Haemost. 2012; 108: 410-411